JP7658916B2 - Ｂｔｋ阻害剤を調製するためのプロセス及び中間体 - Google Patents

Ｂｔｋ阻害剤を調製するためのプロセス及び中間体 Download PDF

Info

Publication number
JP7658916B2
JP7658916B2 JP2021569238A JP2021569238A JP7658916B2 JP 7658916 B2 JP7658916 B2 JP 7658916B2 JP 2021569238 A JP2021569238 A JP 2021569238A JP 2021569238 A JP2021569238 A JP 2021569238A JP 7658916 B2 JP7658916 B2 JP 7658916B2
Authority
JP
Japan
Prior art keywords
compound
formula
ibrutinib
halo
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533747A5 (https=
JP2022533747A (ja
Inventor
パイ，フィリップ，ジェームス
ホルヴァート，アンドラス
チェン，チェン，イ
ユアン，ユアンユアン
ス，ジンション
ワン，シュオ
ワグシャル，サイモン，アルバート
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022533747A publication Critical patent/JP2022533747A/ja
Publication of JP2022533747A5 publication Critical patent/JP2022533747A5/ja
Application granted granted Critical
Publication of JP7658916B2 publication Critical patent/JP7658916B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2021569238A 2019-05-21 2020-05-20 Ｂｔｋ阻害剤を調製するためのプロセス及び中間体 Active JP7658916B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019087823 2019-05-21
CNPCT/CN2019/087823 2019-05-21
PCT/EP2020/064123 WO2020234381A1 (en) 2019-05-21 2020-05-20 Processes and intermediates for preparing a btk inhibitor

Publications (3)

Publication Number Publication Date
JP2022533747A JP2022533747A (ja) 2022-07-25
JP2022533747A5 JP2022533747A5 (https=) 2024-12-09
JP7658916B2 true JP7658916B2 (ja) 2025-04-08

Family

ID=70857160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569238A Active JP7658916B2 (ja) 2019-05-21 2020-05-20 Ｂｔｋ阻害剤を調製するためのプロセス及び中間体

Country Status (11)

Country Link
US (1) US12215110B2 (https=)
EP (1) EP3972977A1 (https=)
JP (1) JP7658916B2 (https=)
KR (1) KR20220011668A (https=)
CN (1) CN113874378A (https=)
AU (1) AU2020278162A1 (https=)
BR (1) BR112021022347A2 (https=)
CA (1) CA3135240A1 (https=)
IL (1) IL288154A (https=)
MX (1) MX2021014246A (https=)
WO (1) WO2020234381A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12450495B2 (en) 2022-06-13 2025-10-21 International Business Machines Corporation Neural capacitance: neural network selection via edge dynamics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538257A (ja) 2013-10-17 2016-12-08 ブループリント メディシンズ コーポレイション Ｋｉｔに関連する疾患を治療するために有用な組成物
JP2018502077A (ja) 2015-01-14 2018-01-25 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤の合成
JP2018513205A (ja) 2015-02-12 2018-05-24 上▲海▼度▲徳▼医▲藥▼科技有限公司 イブルチニブの製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2526933T3 (en) * 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
PT2414363E (pt) * 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
CA2901510C (en) * 2013-03-15 2022-11-29 Janssen Pharmaceutica Nv Processes for preparing ibrutinib derivatives and intermediates thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538257A (ja) 2013-10-17 2016-12-08 ブループリント メディシンズ コーポレイション Ｋｉｔに関連する疾患を治療するために有用な組成物
JP2018502077A (ja) 2015-01-14 2018-01-25 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤の合成
JP2018513205A (ja) 2015-02-12 2018-05-24 上▲海▼度▲徳▼医▲藥▼科技有限公司 イブルチニブの製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chen, Cheng-yi et al.，A Copper-Catalyzed Tandem C-H ortho-Hydroxylation and N-N Bond-Formation Transformation: Expedited Synthesis of 1-(ortho-Hydroxyaryl)-1H-indazoles，European Journal of Organic Chemistry ，2017年，2017(45)，6604-6608，DOI: 10.1002/ejoc.201701149
Chen, Cheng-yi et al.，A Synthesis of 1H-Indazoles via a Cu(OAc)2-Catalyzed N-N Bond Formation，Organic Letters，2016年，18(7)，1690-1693，DOI: 10.1021/acs.orglett.6b00611

Also Published As

Publication number Publication date
EP3972977A1 (en) 2022-03-30
KR20220011668A (ko) 2022-01-28
BR112021022347A2 (pt) 2022-01-04
AU2020278162A1 (en) 2021-11-18
IL288154A (en) 2022-01-01
BR112021022347A8 (pt) 2021-12-28
US20220204516A1 (en) 2022-06-30
JP2022533747A (ja) 2022-07-25
CN113874378A (zh) 2021-12-31
MX2021014246A (es) 2022-01-06
CA3135240A1 (en) 2020-11-26
WO2020234381A1 (en) 2020-11-26
US12215110B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
AU2013203283B2 (en) Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine
CN111763209B (zh) 一种芦可替尼的合成工艺
JP6777398B2 (ja) 薬剤を調製するための方法と中間体
US9156847B2 (en) Processes and intermediates for preparing a medicament
EP3148968B1 (en) Processes for the preparation of beta-aminosulfone compounds
JP7658916B2 (ja) Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
EP2595966B1 (en) Synthesis of cyclopentaquinazolines
RU2818458C2 (ru) Способы и промежуточные соединения для получения ингибитора btk
JP7515510B2 (ja) （３ｒ，４ｒ）－１－ベンジル－ｎ，４－ジメチルピペリジン－３－アミンまたはその塩の製造方法、およびそれを使用したトファシチニブの製造方法
HK40060540A (en) Processes and intermediates for preparing a btk inhibitor
JP7774448B2 (ja) Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
WO2001060795A1 (en) Processes for preparing optically active amino acid derivatives
CN111471020B (zh) 一种阿普替尼中间体的制备方法
HK40053467A (en) Processes for the preparation of (s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine
HK40035220A (en) Processes for the preparation of (s)-1-(3-ethoxy-4- methoxyphenyl)-2-methanesulfonylethylamine
HK40035220B (en) Processes for the preparation of (s)-1-(3-ethoxy-4- methoxyphenyl)-2-methanesulfonylethylamine
JP2005255659A (ja) 官能基化された中員環アミン類とその製法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241021

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250327

R150 Certificate of patent or registration of utility model

Ref document number: 7658916

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150